spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Graft Versus Host 

 HSMN NewsFeed - 15 Dec 2021
FDA Approves First Drug to Prevent Graft Versus Host Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Mar 2021
CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Mar 2019
Allogeneic CAR-T Specialists TC BioPharm Appoint Prof John Anderson as Scientific and Medical Director
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 May 2018
Refuge Biotechnologies Completes $25 Million Series B Financing, Appoints CSO to Advance the Development of Intelligent Cell Therapies in Oncology
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 20 Mar 2018
Ocugen Reports Positive Phase 2 Clinical Results Demonstrating Proof-of-Concept for its Novel Combination Therapy for Dry Eye Disease
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 5 Sep 2017
FDA Grants Orphan Drug Status to Cellect's ApoGraft(TM) for Acute GvHD and Chronic GvHD
Regenerative Medicine FDA
 HSMN NewsFeed - 9 Aug 2017
Ocugen Receives FDA Orphan Drug Designation for OCU300 (brimonidine tartrate) for the Treatment of Ocular Graft Versus Host Disease
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 19 Jun 2017
Ocugen Makes Strategic Appointments to Management Team
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 28 Jan 2016
Cynata Receives Favourable Advice from UK Regulatory Authority
Regenerative Medicine Regulatory
 HSMN NewsFeed - 27 Aug 2014
Bellicum Pharmaceuticals Secures $55 Million in Oversubscribed Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 Apr 2014
Grafix(R) Pharmacoeconomic and Scientific Characterization Studies Featured at the 2014 Spring Symposium for Advanced Wound Care
Devices Regenerative Medicine Wound Care
 HSMN NewsFeed - 26 Mar 2014
Osiris Therapeutics Announces Therésa K. Dixon as General Manager of Market Access and Reimbursement
Regenerative Medicine Personnel
 HSMN NewsFeed - 12 Feb 2014
Osiris Therapeutics Promotes Frank Czworka to Vice President and General Manager of Wound Care
Devices Regenerative Medicine Wound Care Personnel
 HSMN NewsFeed - 14 Jan 2014
Osiris Therapeutics Board Confirms Lode Debrabandere, PhD, MBA, as President and Chief Executive Officer
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 9 Jan 2014
Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies
Biopharmaceuticals
 HSMN NewsFeed - 7 Jan 2014
Bellicum Pharmaceuticals Raises $34.4 Million in a Series B Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 18 Dec 2013
America Stem Cell, Inc. Changes Its Name to Targazyme, Inc.
Biopharmaceuticals Regenerative Medicine Oncology
 HSMN NewsFeed - 29 Nov 2013
Osiris Provides Update on Proposed Ruling by CMS
Devices Regenerative Medicine Wound Care Reimbursement
 HSMN NewsFeed - 18 Nov 2013
Kiadis Pharma Provides Positive Update on its Phase II Clinical Program with Blood Cancer Treatment ATIR(TM)
Biopharmaceuticals
 HSMN NewsFeed - 14 Nov 2013
Defibrotide Granted Orphan Drug Status in Australia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Dec 2012
Omni Bio Pharmaceutical Appoints New CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Apr 2012
Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 8 Sep 2009
Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GvHD Trials
Biopharmaceuticals
 HSMN NewsFeed - 19 Aug 2009
Gentium Reports Top Line Results from the Phase III Treatment Trial of Defibrotide for Severe Veno-Occlusive Disease
Biopharmaceuticals
 HSMN NewsFeed - 12 Feb 2009
Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction
Regenerative Medicine Cardiology
 HSMN NewsFeed - 5 Dec 2008
Osiris Receives Approval for Prochymal Expanded Access Program in Canada
Biopharmaceuticals Regenerative Medicine Regulatory
 HSMN NewsFeed - 28 Jul 2008
Osiris Therapeutics Appoints Chief Financial Officer
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 8 May 2008
Osiris and NuVasive Enter into Definitive Agreement for Osteocel(R)
Regenerative Medicine
 HSMN NewsFeed - 8 May 2008
Osiris Receives Approval for Use of Prochymal(TM) Under FDA Expanded Access Treatment Program
Regenerative Medicine FDA
 HSMN NewsFeed - 6 May 2008
REGiMMUNE Raises $8,000,000 in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 15 Apr 2008
Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Feb 2008
Osiris Therapeutics Strengthens Management Team
Regenerative Medicine Personnel
 HSMN NewsFeed - 7 Jan 2008
Osiris Therapeutics Regains Worldwide Rights to Cardiovascular Indications for Prochymal(TM)
Regenerative Medicine Cardiology
 HSMN NewsFeed - 10 Dec 2007
Osiris Therapeutics Reports Positive Results for Prochymal(TM) as a Rescue Agent in Pediatric Patients with End-Stage Graft vs. Host Disease
Regenerative Medicine
 HSMN NewsFeed - 27 Nov 2007
Osiris Therapeutics Announces Positive One Year Data from Chondrogen Trial for Knee Repair
Regenerative Medicine Orthopaedic
 HSMN NewsFeed - 23 Nov 2007
Osiris Therapeutics Announces Management Change
Regenerative Medicine Personnel
 HSMN NewsFeed - 6 Nov 2007
First Patient Undergoes Expanded Cord Blood Transplant in the ExCell Registration Study of StemEx(R) for Leukemia and Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Oct 2007
Osiris Therapeutics Secures $30 Million Financing Commitment from Chairman and Largest Shareholder
Regenerative Medicine
 HSMN NewsFeed - 20 Mar 2007
DOR BioPharma Forms orBec(R) Medical Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2007
Osiris Therapeutics Receives FDA Fast Track Status for Its Crohn's Disease Stem Cell Therapy and Clearance to Start Phase III Clinical Trial
Regenerative Medicine Gastroenterology
 HSMN NewsFeed - 9 Nov 2006
Noxafil(R) (Posaconazole) Oral Suspension Approved in European Union for Prevention of Invasive Fungal Infections
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Sep 2006
European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (posaconazole) Oral Suspension for Prevention of Invasive Fungal Infections
Biopharmaceuticals Regulatory
Return to NewsFeed  

 Additional items found! 12

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 12 additional stories matching:
Graft Versus Host
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.